Hillsdale Investment Management Inc. Has $562,000 Position in Hologic, Inc. (NASDAQ:HOLX)

Hillsdale Investment Management Inc. lowered its holdings in Hologic, Inc. (NASDAQ:HOLX) by 13.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,800 shares of the medical equipment provider’s stock after selling 1,200 shares during the period. Hillsdale Investment Management Inc.’s holdings in Hologic were worth $562,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Sei Investments Co. raised its holdings in Hologic by 7.2% in the 4th quarter. Sei Investments Co. now owns 1,504,503 shares of the medical equipment provider’s stock valued at $108,460,000 after acquiring an additional 101,542 shares in the last quarter. American Century Companies Inc. increased its position in shares of Hologic by 14.1% in the fourth quarter. American Century Companies Inc. now owns 1,274,067 shares of the medical equipment provider’s stock worth $91,848,000 after purchasing an additional 157,731 shares during the period. Mizuho Securities USA LLC lifted its position in Hologic by 46.2% during the fourth quarter. Mizuho Securities USA LLC now owns 22,014 shares of the medical equipment provider’s stock worth $1,587,000 after purchasing an additional 6,952 shares during the period. Sciencast Management LP acquired a new stake in Hologic during the fourth quarter worth about $694,000. Finally, TD Private Client Wealth LLC increased its holdings in Hologic by 47.5% in the 4th quarter. TD Private Client Wealth LLC now owns 7,115 shares of the medical equipment provider’s stock valued at $513,000 after buying an additional 2,290 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HOLX has been the topic of several analyst reports. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Evercore ISI decreased their price target on Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research note on Thursday, February 6th. Raymond James reissued an “outperform” rating and set a $90.00 price target (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, Morgan Stanley lowered their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Trading Up 0.7 %

HOLX opened at $61.89 on Tuesday. The company’s 50 day moving average price is $65.89 and its two-hundred day moving average price is $73.81. The firm has a market capitalization of $13.89 billion, a price-to-earnings ratio of 19.52, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a fifty-two week low of $60.34 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.